Crohn's Disease Pipeline Insight, 2025

Strategic Insights -

The Crohn's disease pipeline is booming with 180+ active players working on 200+ pipeline therapies, says DelveInsight's recent report. This translates to a robust treatment landscape with a plethora of drugs in various stages of development, from early-stage products to late-stage products. The report highlights key companies such as Anssen, RedHill Biopharma, Amgen, Pfizer, and Prometheus Biosciences, which are actively involved in the development of innovative therapeutics for Crohn's disease. The report also showcases promising pipeline therapies, including Ozanimod, Etrasimod, CBP-307, and IMU-856, which hold significant potential in improving the treatment landscape for patients with Crohn's disease.

Key Takeaways:

  • DelveInsight's report highlights the active involvement of 180+ companies in the development of 200+ pipeline therapies for Crohn's disease treatment.
  • The report emphasizes the approval of OMVOH (mirikizumab-mrkz) infusion in October 2023, which marked the first interleukin-23p19 antagonist approved for treating moderately to severely active ulcerative colitis in adults.
  • RINVOQ's (upadacitinib) approval in May 2023 for the treatment of adults with moderately to severely active Crohn's disease who have not responded adequately or are intolerant to one or more TNF blockers is another significant milestone.
  • Bristol-Myers Squibb stands out with its drug candidates reaching the most advanced phase of development in Phase III clinical trials.
  • The report provides detailed insights into the pre-clinical and discovery stage candidates, discontinued, and inactive candidates, making it an essential resource for stakeholders in the Crohn's disease market.
  • Promising pipeline therapies in various stages of development, including Ozanimod, Etrasimod, CBP-307, and IMU-856, indicate significant potential in improving the treatment landscape for patients with Crohn's disease.

Statistics:

  • 180+ active players are working on 200+ pipeline therapies for Crohn's disease treatment.
  • OMVOH (mirikizumab-mrkz) infusion is the first interleukin-23p19 antagonist approved for treating moderately to severely active ulcerative colitis in adults (October 2023).
  • RINVOQ (upadacitinib) approval for the treatment of adults with moderately to severely active Crohn's disease is another significant milestone (May 2023).
  • 70+ leading companies are engaged in developing therapies for Crohn's disease, with Bristol-Myers Squibb leading the charge with its drug candidates reaching the most advanced phase of development in Phase III clinical trials.

Sources:

  • M2 PressWIRE (July 9, 2025)
  • DelveInsight's report "Crohn's disease Pipeline Insight, 2025"
  • "Crohn's disease - Pipeline Insight, 2025" report by DelveInsight provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Crohn's disease pipeline landscape.